The Leukemia & Lymphoma Society published a study showing that more than one in two patients with B-cell blood cancers produced antibodies to a third dose of COVID-19 vaccine, despite having no detectable antibodies after the first two doses.
At a time when federal immigration policies are becoming stricter, Kunle Odunsi, director of University of Chicago Medicine Comprehensive Cancer Center, reflected on the fact that cancer research is a highly international community.
